IMAGE: These are the HCI physicians from left to right: Paul Shami, M.D., Tibor Kovacsovics, M.D. and Michael Deininger, M.D., Ph.D. view more
Credit: Jonathan Martinez, Huntsman Cancer Institute
SALT LAKE CITY – Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.
AML is a type of blood cancer that begins in the bone marrow and, in most cases, progresses rapidly if not treated. According to the National Cancer Institute, in 2018, more than 21,000 individuals will be diagnosed with AML in the United States and approximately 10,650 will die from the disease. Although several new drugs were approved for AML in 2017, most current treatments for AML are based on principles developed 40 years ago. The clinical trial intends to provide significant improvements to the standard care for this disease based on the use of molecular screening for
Article originally posted at